Thalidomide-PEG2-C2-NH2 is a specialized derivative used primarily in the development of targeted cancer therapies as a payload component in antibody-drug conjugates (ADCs). The PEG2-C2 linker and terminal amine group enable conjugation to antibodies, facilitating precise delivery of the immunomodulatory thalidomide moiety to cancer cells while minimizing off-target effects on healthy tissues. It is also utilized in prodrug research to enhance the solubility and bioavailability of therapeutic agents. Furthermore, this compound supports studies on immunomodulatory drugs, improving treatment efficacy for conditions such as multiple myeloma and erythema nodosum leprosum (ENL) in leprosy. Its design promotes controlled drug release and targeted delivery, making it essential for advanced pharmaceutical formulations.